Related Experiment Video
Updated: Apr 21, 2026
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
2.0K
Enteric Budesonide Treatment in IgA Nephropathy
Sanjeev Gulati1, Arpita Roy Chaudhary2,3, Sanshriti Chauhan1
1Department of Nephrology & Kidney Transplant, Fortis Flt. Lt. Rajan Dhall Hospital, Fortis Group of Hospitals, Vasant Kunj, New Delhi, India.
Kidney International Reports
|April 20, 2026
Summary
Enteric coated budesonide effectively reduced proteinuria and stabilized kidney function in IgA nephropathy patients. This accessible treatment shows promise where other options are unavailable.
Area of Science:
- Nephrology
- Pharmacology
- Immunology
Background:
- Targeted release formulation (TRF)-budesonide is approved for IgA nephropathy (IgAN) but not globally available.
- Enteric coated (EC)-budesonide is widely accessible, yet IgAN-specific data is limited.
Purpose of the Study:
- To evaluate the efficacy and safety of EC-budesonide in adult IgAN patients.
- To assess proteinuria and kidney function changes over 9 months.
Main Methods:
- Prospective, single-arm, multicenter study of 168 adult, immunosuppressive-naïve IgAN patients.
- Administered EC-budesonide (9 mg twice daily) with maximally tolerated supportive care.
- Primary outcome: urine albumin creatinine ratio (UACR) reduction at 9 months; secondary: eGFR change and response rates.
Main Results:
- Significant UACR reduction of 66.3% at 9 months (P < 0.001).
- High response rates: 88.5% achieved ≥30% UACR reduction, 75.7% achieved ≥50% reduction.
- Mean eGFR improved by +5.0 ml/min/1.73 m² (P < 0.001); outcomes consistent across subgroups.
Conclusions:
- EC-budesonide demonstrated encouraging safety, proteinuria reduction, and eGFR stabilization in IgAN.
- This formulation shows promising efficacy in regions lacking other approved therapies.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
01:21Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
684
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
684
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.0K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K